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Thrombin-activatable fibrinolysis
inhibitor and its relation with
inflammation in rheumatoid arthritis
Rheumatoid arthritis (RA) is associated with an excessive risk of
cardiovascular morbidity and mortality, and inflammation
appears to be the missing link explaining this markedly elevated
risk.1 Inflammation is a potent inducer of coagulation and
fibrinolysis and may contribute to atherosclerotic and throm-
botic components of cardiovascular events.2 Thrombin-activa-
table fibrinolysis inhibitor (TAFI), a procarboxypeptidase in
plasma, is a regulatory protein of the coagulation/fibrinolysis
balance as well as inflammation. TAFIa, the activated form of
TAFI, acts by removing C-terminal arginine and lysine residues
from substrates such as fibrin degradation products, bradykinin
and the anaphylatoxins C3a and C5a. Elevated TAFI levels may
reflect an enhanced risk of developing cardiovascular disease,
although evidence for this is somewhat contradictory since the
Table 1 Characteristics from patients with rheumatoid arthritis (RA) in high versus low inflammatory state
CRP.10 mg/litre CRP,10 mg/litre p Value
Demographic:
Age (years) 63 (9) 63 (8) 0.74
Men, % 33 33 0.97
Disease activity:
CRP (mg/litre) 59 (51 to 72) 1 (1) ,0.01
ESR (mm/h) 61 (47 to 71) 10 (5 to 11) ,0.01
DAS28 (0–10) 5.5 (1.0) 3.0 (1.1) ,0.01
Disease duration (years) 7 (4 to 10) 8 (5 to 10) 0.97
Disease severity:
Erosions, % 62 95 0.01
RF positive, % 80 76 0.77
Drug therapy:
NSAIDs, % 76 67 0.50
Methotrexate, % 52 67 0.37
Prednisone, % 33 24 0.50
Calcium suppletion, % 33 24 0.50
Aspirin, % 14 19 0.68
Statin, % 5 33 0.02
TAFI polymorphisms:
Thr147Ala
Thr/Thr, % 5 0 0.44
Thr/Ala, % 52 52
Ala/Ala, % 43 48
Thr325IIe
Thr/Thr, % 48 29 0.59
Thr/Ile, % 43 57
lle/lle, % 9 14
TAFI levels (%) 147 (129 to 163) 114 (102 to 127) ,0.01
Data are expressed as mean (SD), median (interquartile ranges (IQR)), or as percentages of the total (%). Differences in baseline
characteristics between both groups were evaluated by using independent t tests for normally distributed variables, Mann–Whitney U
tests for skewed variables and Pearson x2 tests for dichotomous variables. Significant results are in bold.
CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-
inflammatory drug; RF, rheumatoid factor; TAFI, thrombin-activatable fibrinolysis inhibitor.
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use of genotype-sensitive assays complicates interpretation of the
data.3–5 Furthermore, TAFI levels associate with acute phase
reactants in patients with cardiovascular disease and are elevated
in patients with RA, as compared with non-RA controls.6 7 TAFI’s
dual function in regulating haemostatic and inflammatory
processes makes it an interesting protein to study in relation to
RA. The objective of this study was to determine TAFI levels and
its relation with inflammation in patients with RA.
In this study, the serum C-reactive protein (CRP) concentra-
tion was used to express the level of inflammation. A total of 21
patients with RA with normal CRP levels (low inflammatory
state; ,10 mg/litre) and 21 age-matched and sex-matched
patients with RA with elevated CRP levels (high inflammatory
state) were selected for evaluation of TAFI levels. All patients
with RA attended the outpatient clinic at the Jan van Breemen
Institute (Amsterdam, The Netherlands) where they were seen
by a research doctor, and completed a questionnaire recording
demographic data, medical and medication history (table 1).
The local ethics committees approved the study protocol and all
participants signed a written informed consent. TAFI levels
were determined with a genotype-insensitive kinetic activity
assay in which the zymogen is first quantitatively converted to
TAFIa, as described previously.8 TAFI levels were expressed as
the percentage of a plasma pool of 20 healthy volunteers.
TAFI levels were significantly higher in patients with RA
with elevated CRP levels. These differences disappeared after
adjustment for inflammation by means of erythrocyte sedi-
mentation rate (ESR) or 28-joint Disease Activity Score
(DAS28). Separate adjustments for potential other confounders
(ie, age, gender, disease duration, IgM-rheumatoid factor (RF),
the use of statins, aspirin, calcium suppletion, non-steroidal
anti-inflammatory drugs (NSAIDs), prednisone or methotrex-
ate) did not change these results. No differences in TAFI levels
in this small population were found between patients with RA
stratified for the TAFI polymorphisms 147 and 325.
In conclusion, we report that TAFI levels are significantly
higher in the plasma of patients with RA with a high
inflammatory state. This finding supports the need for prospec-
tive studies investigating the association between TAFI levels and
cardiovascular disease as, on the one hand, high TAFI levels may
facilitate the development of cardiovascular comorbidity by
shifting the haemostatic balance to a more hypofibrinolytic state
and, on the other hand, TAFI levels may relate to the body’s
mechanisms dampening the excessive inflammatory reaction
found in patients with RA.
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Bilateral parotid gland involvement
in Wegener granulomatosis
Wegener granulomatosis (WG) is a disease characterised by
granulomatous inflammation and a vasculitis predominantly
affecting small vessels.1 We describe a patient with WG who
presented with bilateral parotid gland involvement, which is
particularly unusual.
An 18-year-old woman with asthma presented with symp-
toms consistent with sinusitis with bilateral parotid gland
swelling. She was treated with antibiotics over a 4-week period.
Her symptoms failed to improve and she developed an enlarged
lacrimal gland 2 months later, associated with 10 kg weight loss
and lower limb arthralgia. Her C-reactive protein was 187 mg/l
(normal ,5 mg/l) and her erythrocyte sedimentation rate was
56 mm/h (normal 1–10 mm/h). A biopsy of the left parotid
gland showed poorly formed granulomas. A day after the
biopsy, she developed a seventh nerve palsy on the opposite
side. After 2 weeks the right parotid gland was biopsied,
showing similar histological findings. A presumptive diagnosis
of sarcoidosis was made and she was given a reducing regime of
prednisolone (starting at 60 mg daily) with hydroxychloroquine
200 mg twice daily. The parotid gland swellings did not
improve and she later developed nasal bridge collapse with
associated epistaxis and was referred to our unit.
Investigations revealed a neutrophilia, but otherwise normal
full blood count, normal serum biochemistry (with an estimated
glomerular filtration rate of 113 ml/min) and normal urine
microscopy. All autoantibodies were negative (including anti-
nuclear antibody and extractable nuclear antigen screen) except
for anti-proteinase 3 anti-neutrophil cytoplasmic antibodies
(PR3-ANCA), which were mildly elevated at 9 U/ml
(normal,5 U/ml). Respiratory function tests and a CT scan
of her chest were normal. A CT scan of her neck and sinuses
showed enlarged parotid glands and revealed extensive defects
within the nasal septum, face of the sphenoid nasal bridge and
medial maxillary antra. A biopsy of the paranasal sinus and
right nasal septum showed a necrotising granuloma with
evidence of a vasculitis consistent with WG (fig 1).
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